Lexicon Pharmaceuticals LXRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.09M+48.2% | -$50.34M+26.6% | -$68.58M+43.1% | -$120.62M+32.0% | -$177.3M+11.5% | ||
| $555K-10.6% | $621K-1.1% | $628K+4.1% | $603K+6.5% | $566K+6.0% | ||
| $12.55M+0.3% | $12.52M+11.6% | $11.22M+6.1% | $10.58M-13.6% | $12.24M-9.3% | ||
| $1.98M+16.5% | $1.7M+5.9% | $1.61M0.0% | $1.61M-7.1% | $1.73M-6.3% | ||
| —— | —— | —— | -$437K-147% | $921K-62.6% | ||
| $75K+50.0% | $50K+110% | -$478K-14.6% | -$417K-33.2% | -$313K-109% | ||
| —— | —— | —— | —— | $2.22M-85.0% | ||
| —— | —— | —— | —— | -$3.69M-517% | ||
| $783K-55.1% | $1.74M+39.6% | $1.25M+255% | $352K-81.5% | $1.9M+334% | ||
| —— | —— | —— | —— | -$167.43M+6.3% | ||
| $180.83M+29.3% | $139.84M-2.5% | $143.49M-10.0% | $159.39M-24.3% | $210.49M-36.0% | ||
| $183M-27.6% | $252.86M-17.3% | $305.86M-5.4% | $323.41M-6.8% | $346.95M+10.4% | ||
| $2.18M-98.1% | $113.02M— | —— | —— | —— | ||
| $53M+10.4% | $48M+6.7% | $45M0.0% | $45M— | —— | ||
| $69.99M— | $0— | $0— | $0+100% | -$88K— | ||
| —— | —— | —— | —— | —— | ||
| $26.55M— | $0— | —— | —— | —— | ||
| $40.83M+184% | -$48.5M— | —— | —— | —— | ||
| $4.2M+226% | -$3.33M-108% | $44.11M— | —— | —— | ||
| $6.84M-17.9% | $8.33M-14.7% | $9.77M-13.5% | $11.3M-10.6% | $12.63M-2.2% | ||
| $2.95M-20.6% | $3.71M-28.0% | $5.16M-27.7% | $7.13M-22.7% | $9.23M-0.8% | ||
| $1.98M+16.5% | $1.7M+5.9% | $1.61M0.0% | $1.61M-7.1% | $1.73M-6.3% | ||
| -$766K-1.2% | -$757K+37.2% | -$1.21M-1.3% | -$1.19M-1.6% | -$1.17M-1.7% | ||
| —— | —— | —— | —— | -$3.69M-517% | ||
| $783K-55.1% | $1.74M+39.6% | $1.25M+255% | $352K-81.5% | $1.9M+334% | ||
| $183M-27.6% | $252.86M-17.3% | $305.86M-5.4% | $323.41M-6.8% | $346.95M+10.4% | ||
| $26.55M— | $0— | —— | —— | —— | ||
| $138K+89.0% | $73K— | —— | —— | —— | ||
| $53M+10.4% | $48M+6.7% | $45M0.0% | $45M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Lexicon Pharmaceuticals generate?
- Lexicon Pharmaceuticals (LXRX) generated -$99.6M in operating cash flow over the trailing twelve months.
- Where does Lexicon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
